Anixa Biosciences (NASDAQ:ANIX) Director Arnold Baskies Acquires 5,000 Shares of Company Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Arnold Baskies bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 24th. The stock was bought at an average price of $2.76 per share, with a total value of $13,800.00. Following the transaction, the director directly owned 140,572 shares in the company, valued at $387,978.72. This represents a 3.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Anixa Biosciences Trading Up 0.4%

Anixa Biosciences stock opened at $2.79 on Tuesday. Anixa Biosciences Inc has a 52 week low of $2.32 and a 52 week high of $5.46. The stock has a market cap of $96.98 million, a price-to-earnings ratio of -8.72 and a beta of 0.51. The company’s 50-day moving average price is $3.23 and its two-hundred day moving average price is $2.97.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). Research analysts expect that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ANIX shares. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. HC Wainwright cut their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Finally, Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Investors Weigh In On Anixa Biosciences

Several large investors have recently modified their holdings of ANIX. Integrated Wealth Concepts LLC acquired a new position in shares of Anixa Biosciences in the 2nd quarter worth $30,000. Corient Private Wealth LP lifted its holdings in shares of Anixa Biosciences by 87.0% during the second quarter. Corient Private Wealth LP now owns 37,400 shares of the company’s stock valued at $105,000 after purchasing an additional 17,400 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Anixa Biosciences during the second quarter valued at $41,000. Canada Pension Plan Investment Board acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at $38,000. Finally, Sanctuary Advisors LLC purchased a new position in Anixa Biosciences in the 2nd quarter worth about $29,000. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.